Legacy Capital Wealth Partners LLC Has $544,000 Position in GSK plc (NYSE:GSK)

Legacy Capital Wealth Partners LLC lessened its holdings in GSK plc (NYSE:GSK - Free Report) by 59.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 16,088 shares of the pharmaceutical company's stock after selling 23,681 shares during the period. Legacy Capital Wealth Partners LLC's holdings in GSK were worth $544,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of GSK. Indiana Trust & Investment Management Co raised its position in shares of GSK by 200.0% in the fourth quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company's stock valued at $25,000 after purchasing an additional 500 shares during the period. Eastern Bank acquired a new position in GSK in the 3rd quarter valued at $26,000. Crews Bank & Trust bought a new position in GSK in the 4th quarter worth $26,000. ST Germain D J Co. Inc. lifted its position in GSK by 195.5% during the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company's stock worth $27,000 after acquiring an additional 522 shares during the last quarter. Finally, Sunbelt Securities Inc. boosted its holdings in GSK by 73.8% during the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company's stock valued at $29,000 after acquiring an additional 302 shares during the period. 15.74% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on GSK. StockNews.com upgraded GSK from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 7th. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a "buy" rating to a "hold" rating in a research note on Friday, November 15th. Guggenheim downgraded shares of GSK from a "buy" rating to a "neutral" rating in a report on Thursday, October 31st. Jefferies Financial Group downgraded shares of GSK from a "buy" rating to a "hold" rating and dropped their price objective for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Finally, Morgan Stanley assumed coverage on shares of GSK in a research note on Wednesday, February 12th. They issued an "equal weight" rating for the company. Seven investment analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $43.25.

GSK Price Performance

Shares of NYSE:GSK traded up $0.50 during midday trading on Thursday, reaching $37.04. 6,241,986 shares of the company's stock were exchanged, compared to its average volume of 4,636,272. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. The company's 50 day simple moving average is $34.49 and its two-hundred day simple moving average is $37.38. GSK plc has a 12 month low of $31.72 and a 12 month high of $45.92. The firm has a market capitalization of $76.76 billion, a PE ratio of 23.29, a price-to-earnings-growth ratio of 1.11 and a beta of 0.64.

GSK (NYSE:GSK - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, topping analysts' consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. Equities research analysts expect that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be paid a $0.3932 dividend. This is a positive change from GSK's previous quarterly dividend of $0.39. The ex-dividend date is Friday, February 21st. This represents a $1.57 annualized dividend and a yield of 4.25%. GSK's payout ratio is currently 98.74%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.